Moderna to report fourth quarter and full year 2020 financial results on thursday, february 25, 2021
Cambridge, mass.--(business wire)--moderna, inc. (nasdaq: mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. et on thursday, february 25, 2021 to report its fourth quarter and full year 2020 financial results, and provide a corporate update. to access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference id 4066945. a webcast of the call will also be available under “events and presentations” in the investors section of the moderna website at investors.modernatx.com. the archived webcast will be available on moderna’s website approximately two hours after the conference call and will be available for one year following the call. about moderna in 10 years since its inception, moderna has transformed from a science research-stage company advancing programs in the promising-but-still-unproven field of messenger rna (mrna), to an enterprise with its first medicine having treated millions of people, a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mrna and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. most recently, moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the covid-19 pandemic. moderna’s mrna platform builds on continuous advances in basic and applied mrna science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. today, 24 development programs are underway across these therapeutic areas, with 13 programs having entered the clinic. moderna has been named a top biopharmaceutical employer by science for the past six years. to learn more, visit www.modernatx.com.
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission